scholarly journals Increasing incidence of hepatitis A in Bangladesh

2012 ◽  
Vol 47 (3) ◽  
pp. 309-312 ◽  
Author(s):  
MZ Amin ◽  
LN Siddique ◽  
MA Slatter ◽  
KK Biswas
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Age Groups ◽  
Hepatitis E ◽  
Immunoglobulin M ◽  
Chronic Liver ◽  
High Risk Population

Hepatitis A (HAV) infection is caused by the hepatitis A virus which is transmitted through the fecal-oral route. Life long protective antibodies are present after infection. The number of cases of adult hepatitis A has progressively been increasing during the last several decades in Bangladesh. In addition, the pattern of age-specific seroprevalence of anti-HAV has changed with economic growth. The prevalence of anti-HAV in 20-40 year age range has declined rapidly during the last 3 decades. As a result, this age groups has a high risk for HAV infection and clinically overt hepatitis A is increasing in adolescents and adult. The aim of the present study were to assess whether the proportion of adults with acute HAV infection has been increasing over the years and analyze the seroprevalence of immunoglobulin M(IgM) anti- HAV antibodies in young adults below the age of 20 years as well as in cases of chronic liver disease. Sera collected from 530 patients with acute and chronic liver disease attends the Somorita Hospital Ltd. during the previous 2 years and 6 months (Jan. 2008- Jun. 2010) were tested for various serological markers of acute and chronic hepatitis. In addition, 530 normal healthy attendants of the patients above the age of 20 years were tested for IgM anti-HAV as controls. Of 530 patients with acute hepatitis (13.42%) were positive for immunoglobulin M. The patients who were IgM anti-HAV negative were found to be hepatitis B (106 patients), hepatitis C, (10 patients), hepatitis E (150 patients) and unclassified (273 patients). Although the frequency of HAV infection among young adult (< 20 age) had increased (33.33% to 42.35%) in the 2 years and 6 months period, the frequency of HAV infection among adults had also increased (15.38% to 28.13%) during the same period. This study should be helpful for the identification of high risk population for vaccination of hepatitis A. DOI: http://dx.doi.org/10.3329/bjsir.v47i3.13065 Bangladesh J. Sci. Ind. Res. 47(3), 309-312 2012

scholarly journals Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea

2007 ◽  
Vol 22 (2) ◽  
pp. 218 ◽  
Author(s):  
Hyun Joo Song ◽  
Tae Hun Kim ◽  
Ji Hyun Song ◽  
Hee Jung Oh ◽  
Kum Hei Ryu ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Chronic Liver

scholarly journals Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania

2005 ◽  
Vol 134 (1) ◽  
pp. 95-101 ◽  
Author(s):  
L. A. KONDILI ◽  
P. CHIONNE ◽  
A. PORCARO ◽  
E. MADONNA ◽  
S. TAFFON ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Case Control Study ◽  
Age Groups ◽  
Hepatitis E ◽  
Case Control ◽  
Chronic Liver ◽  
The Mean ◽  
End Stage ◽  
Control Study

SUMMARYA case-control study involving 109 in-patients with chronic liver disease and 190 in-patients with no apparent liver disease was conducted to evaluate the seroprevalence of anti-HEV antibodies and the possible association with chronic liver disease. Among cases, the anti-HEV prevalence was 36·6% which increased significantly by age; among controls, the prevalence was 12·1% (P<0·05) and was similar among age groups <60 years. Among cases, aged >50 years (OR 4·0, 95% CI 1·4–11) and the presence of end stage liver disease (ESLD) (OR 4·3, 95% CI 1·4–12·8) were associated independently with anti-HEV positivity. The mean optical density, determined by anti-HEV immunoenzymatic test, was significantly higher among patients with ESLD, compared to the other patients. These results indicate that there is a high seroprevalence of anti-HEV in patients with chronic liver disease and a possible association between HEV infection and/or anti-HEV production and advanced stage chronic liver disease.

scholarly journals The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea

Gut and Liver ◽  
2011 ◽  
Vol 5 (2) ◽  
pp. 217-220 ◽  
Author(s):  
Hyun Chin Cho ◽  
Yu Jin Kim ◽  
Moon Seok Choi ◽  
Joon Hyeok Lee ◽  
Kwang Cheol Koh ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Seroconversion Rate ◽  
Chronic Liver ◽  
Virus Vaccination ◽  
B Virus

scholarly journals Antibodies to hepatitis A virus in Italian patients with chronic liver disease

2001 ◽  
Vol 127 (2) ◽  
pp. 341-346 ◽  
Author(s):  
E. SAGNELLI ◽  
G. ROSSI ◽  
N. COPPOLA ◽  
C. SCOLASTICO ◽  
M. ONOFRIO ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Hepatitis A ◽  
Southern Italy ◽  
Hepatitis A Virus ◽  
Northern Italy ◽  
Chronic Liver ◽  
Vaccination Strategies ◽  
Immunological Protection

To improve our knowledge for future hepatitis A virus (HAV) vaccination strategies we carried out a multicentre study on naturally acquired immunological protection against HAV in patients with chronic hepatitis in Italy. We enrolled 830 consecutive patients with chronic hepatitis on their first observation at one of the six Italian liver units participating in the study. Six hundred and fifty-eight patients (79·3%) were positive for total anti-HAV and 172 (20·7%) were negative. The anti-HAV negative patients were younger (median age 33, range 11–78) than the anti-HAV positive (median age 56, 18–87). There was a higher prevalence of cases with circulating anti-HAV among the 508 patients residing in southern Italy than in the 322 residing in northern Italy (88·8% vs. 64%, P < 0·001). No significant difference in the anti-HAV prevalence was observed between patients from northern Italy and those from southern Italy aged 0–30 years or in those over 60 years, while in those 31–60 years old there was a higher prevalence of anti-HAV positive patients from southern Italy (90·2% vs. 65·8%, P < 0·0001). Of the patients with liver cirrhosis in this study, only 3 of the 26 (11·5%) from northern Italy and 8 of the 228 (3·5%) from southern Italy had no immunological protection against HAV infection. The data suggest that the number of patients with chronic liver disease without naturally acquired immunity against HAV is substantial in Italy, particularly in the north of the country, and that new vaccination strategies are needed.

P0621 : Hepatitis E virus in patients with decompensated chronic liver disease and alcoholic hepatitis: A UK/French study

2015 ◽  
Vol 62 ◽  
pp. S551
Author(s):  
R.G. Madden ◽  
H. Blasco-Perrin ◽  
A. Stanley ◽  
C. Crossan ◽  
J.G. Hunter ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Alcoholic Hepatitis ◽  
Hepatitis E Virus ◽  
Hepatitis A ◽  
Hepatitis E ◽  
Chronic Liver ◽  
French Study

scholarly journals Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease

2020 ◽  
Vol 21 (17) ◽  
pp. 6384
Author(s):  
Tatsuo Kanda ◽  
Reina Sasaki ◽  
Ryota Masuzaki ◽  
Hiroshi Takahashi ◽  
Taku Mizutani ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Failure ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Chronic Liver Damage ◽  
Acute Insult

Hepatitis A virus (HAV) infection occasionally leads to a critical condition in patients with or without chronic liver diseases. Acute-on-chronic liver disease includes acute-on-chronic liver failure (ACLF) and non-ACLF. In this review, we searched the literature concerning the association between HAV infection and chronic liver diseases in PubMed. Chronic liver diseases, such as metabolic associated fatty liver disease and alcoholic liver disease, coinfection with other viruses, and host genetic factors may be associated with severe hepatitis A. It is important to understand these conditions and mechanisms. There may be no etiological correlation between liver failure and HAV infection, but there is an association between the level of chronic liver damage and the severity of acute-on-chronic liver disease. While the application of an HAV vaccination is important for preventing HAV infection, the development of antivirals against HAV may be important for preventing the development of ACLF with HAV infection as an acute insult. The latter is all the more urgent given that the lives of patients with HAV infection and a chronic liver disease of another etiology may be at immediate risk.

Sign in / Sign up

Export Citation Format

Share Document